
Calliditas Therapeutics AB
STO:CALTX

Intrinsic Value
The intrinsic value of one
CALTX
stock under the Base Case scenario is
696.23
SEK.
Compared to the current market price of 208 SEK,
Calliditas Therapeutics AB
is
Undervalued by 70%.
The Intrinsic Value is calculated as the average of DCF and Relative values:

Valuation History
Calliditas Therapeutics AB
Fundamental Analysis


Revenue & Expenses Breakdown
Calliditas Therapeutics AB
Balance Sheet Decomposition
Calliditas Therapeutics AB
Current Assets | 1.2B |
Cash & Short-Term Investments | 797.3m |
Receivables | 222.6m |
Other Current Assets | 134.6m |
Non-Current Assets | 592.7m |
Long-Term Investments | 27.2m |
PP&E | 59.4m |
Intangibles | 471.7m |
Other Non-Current Assets | 34.5m |
Free Cash Flow Analysis
Calliditas Therapeutics AB
SEK | |
Free Cash Flow | SEK |
Earnings Waterfall
Calliditas Therapeutics AB
Revenue
|
1.6B
SEK
|
Cost of Revenue
|
-104.7m
SEK
|
Gross Profit
|
1.5B
SEK
|
Operating Expenses
|
-1.8B
SEK
|
Operating Income
|
-353.1m
SEK
|
Other Expenses
|
-127.2m
SEK
|
Net Income
|
-480.4m
SEK
|
CALTX Profitability Score
Profitability Due Diligence
Calliditas Therapeutics AB's profitability score is 33/100. The higher the profitability score, the more profitable the company is.

Score
Calliditas Therapeutics AB's profitability score is 33/100. The higher the profitability score, the more profitable the company is.
CALTX Solvency Score
Solvency Due Diligence
Calliditas Therapeutics AB's solvency score is 45/100. The higher the solvency score, the more solvent the company is.

Score
Calliditas Therapeutics AB's solvency score is 45/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
CALTX Price Targets Summary
Calliditas Therapeutics AB
Dividends
Current shareholder yield for CALTX is
.
Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?
The intrinsic value of one
CALTX
stock under the Base Case scenario is
696.23
SEK.
Compared to the current market price of 208 SEK,
Calliditas Therapeutics AB
is
Undervalued by 70%.